Newly Published Data Show Efficacy and Safety of Spracor's Lunesta in Elderly Patients with Insomnia
Study data showed that LUNESTA 2 mg was associated with a significantly (p less than 0.05) reduced time to sleep onset, reduced wake time after sleep onset (WASO), increased sleep efficiency and increased total sleep time (TST). In this study, LUNESTA was generally well tolerated with the most frequently reported adverse events being pain, dry mouth, dizziness, somnolence and unpleasant taste.Lunesta is a prescription sleep aid marketed by Sepracor.
Source: Sepracor
Comment Preview